Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Dr...
April 28 2021 - 10:13AM
Business Wire
Poster presentation to address the preclinical
cannabidiol derivative for the potential treatment of psychiatric
disorders
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage
pharmaceutical company committed to extending healthy lifespan by
focusing on developing two therapeutic platforms, announced today
that researchers from the Johns Hopkins University School of
Medicine will present the results of new research on the company’s
compound Supera-CBD at the 3rd Annual Neuroimmunology Drug
Development Summit. The poster presentation will discuss the
preclinical cannabidiol (CBD) derivative that targets endogenous
cannabinoid receptor type 2 for the treatment of psychiatric
disorders. The researchers studied the compound in depression and
anxiety-related phenotypes in mice.
“This presentation of preclinical research will highlight the
potential of Supera-CBD to address unmet needs in psychiatry," said
Adam Kaplin, M.D., Ph.D., Chief Scientific Officer of MyMD
Pharmaceuticals.
Researchers Chantelle Terrillion, Ph.D., Instructor in
Neuroscience, and Anupama Kumar, MBBS, Research Associate in
Psychiatry and primary investigator on the study, will present
findings from preclinical studies on the role of Supera-CBD. Early
findings revealed Supera-CBD’s potent anxiolytic properties. The
data being presented at the conference also demonstrate that
Supera-CBD binds to CB2 with almost four-times the affinity of CBD.
Other research has shown that binding to CB2 potentially mediates a
number of the therapeutic effects of CBD, including its anxiolytic,
antinociceptive, anticonvulsant, antipsychotic, neuroprotective and
anti-inflammatory effects.
Details of the poster presentation are as follows:
Title: Supera-CBD: A Novel CBD Derived Drug Candidate
Abstract Number: 1858
Date and Time: April 28, 2021 at 4:15 p.m. ET.
Access to Poster: The poster will be available at the
conference website’s media library as well as on
MyMD.com/pipeline/supera-cbd after the time noted above.
About MyMD Pharmaceuticals, Inc.
MyMD is a clinical stage pharmaceutical company committed to
extending healthy lifespan by focusing on developing two
therapeutic platforms. MYMD-1 is a drug platform based on a
clinical stage small molecule that regulates the immunometabolic
system to control TNF-α and other pro-inflammatory cytokines.
MYMD-1 is being developed to treat autoimmune diseases, including
those currently treated with non-selective TNF-α blocking drugs,
and aging and longevity. Supera-CBD is a drug platform based on a
novel (patent pending) synthetic derivative of cannabidiol (CBD)
that targets numerous key receptors including CB2 and opioid
receptors and inhibits monoamine oxidase. Supera-CBD is being
developed to address the rapidly growing CBD market, that includes
FDA approved drugs and CBD products not currently regulated as a
drug. For more information, visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates, the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates, the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the registration statement on Form S-4 filed
by MyMD on January 15, 2021, as amended. Forward-looking statements
speak only as of the date they are made and MyMD disclaims any
intention or obligation to revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210428005725/en/
Investor Contact: Brett Mass 646-536-7331
brett@haydenir.com www.haydenir.com
Media Contact: Will Johnson 201-465-8019
MYMD@antennagroup.com www.antennagroup.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Apr 2023 to Apr 2024